This company has been marked as potentially delisted and may not be actively trading. NASDAQ:LUMO Lumos Pharma (LUMO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Lumos Pharma Stock (NASDAQ:LUMO) 30 days 90 days 365 days Advanced Chart Get Lumos Pharma alerts:Sign Up Key Stats Today's Range$4.34▼$4.3450-Day Range$4.30▼$4.4152-Week Range$1.37▼$4.58VolumeN/AAverage Volume96,055 shsMarket Capitalization$37.54 millionP/E RatioN/ADividend YieldN/APrice Target$8.63Consensus RatingBuy Company Overview Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas. Read More Receive LUMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lumos Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address LUMO Stock News HeadlinesLumos House is Back in Austin: Exclusive Events for Founders and BuildersMarch 4, 2025 | reuters.comLumos Pharma Completes Merger and Delisting ProcessDecember 12, 2024 | tipranks.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.July 8 at 2:00 AM | Brownstone Research (Ad)Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos PharmaDecember 12, 2024 | globenewswire.comLumos Pharma reports sustained growth in PGHD trialsNovember 23, 2024 | uk.investing.comLumos announces new analyses of data from OraGrowtH210, OraGrowtH212 trialsNovember 21, 2024 | markets.businessinsider.comHold Rating on Lumos Pharma Amid Financial Challenges and Strategic Merger with Double Point VenturesNovember 10, 2024 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Lumos Pharma Inc. – LUMONovember 6, 2024 | globenewswire.comSee More Headlines LUMO Stock Analysis - Frequently Asked Questions How were Lumos Pharma's earnings last quarter? Lumos Pharma, Inc. (NASDAQ:LUMO) announced its earnings results on Thursday, November, 7th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.34. The business had revenue of $0.73 million for the quarter, compared to analyst estimates of $0.50 million. Lumos Pharma had a negative net margin of 1,583.49% and a negative trailing twelve-month return on equity of 233.03%. What other stocks do shareholders of Lumos Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lumos Pharma investors own include uniQure (QURE), Clean Energy Fuels (CLNE), ACADIA Pharmaceuticals (ACAD), Bicycle Therapeutics (BCYC), Curaleaf (CURLF), Paycom Software (PAYC) and Vale (VALE). Company Calendar Last Earnings11/07/2024Today7/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LUMO CIK1126234 Webwww.lumos-pharma.com Phone(512) 215-2630Fax515-296-3520Employees30Year FoundedN/APrice Target and Rating Average Price Target for Lumos Pharma$8.63 High Price Target$13.00 Low Price Target$4.25 Potential Upside/Downside+98.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($4.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.03 million Net Margins-1,583.49% Pretax Margin-1,583.49% Return on Equity-233.03% Return on Assets-129.88% Debt Debt-to-Equity RatioN/A Current Ratio2.66 Quick Ratio2.66 Sales & Book Value Annual Sales$2.21 million Price / Sales17.02 Cash FlowN/A Price / Cash FlowN/A Book Value$3.45 per share Price / Book1.26Miscellaneous Outstanding Shares8,649,000Free Float6,452,000Market Cap$37.54 million OptionableNot Optionable Beta0.74 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:LUMO) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredNobel Prize Material Finally Goes CommercialA Nobel Prize–winning material just got its biggest breakthrough in 30 years. A little-known company has cr...True Market Insiders | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lumos Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lumos Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.